智通财经网·2026-02-03 07:57Core Viewpoint - The report from CMB International maintains a target price of HKD 136 for Rongchang Biologics (09995) and keeps a "Buy" rating, anticipating that the company will achieve or approach breakeven in its main business by Q4 2025, earlier than previously expected [1] Group 1: Revenue and Profit Forecast - The company is projected to achieve approximately RMB 3.25 billion in revenue for the full year of 2025, representing a year-on-year growth of about 89% [2] - Expected net profit for 2025 is around RMB 716 million, with a non-GAAP net profit of approximately RMB 78.5 million, both indicating a turnaround from losses compared to the previous year [2] Group 2: Drivers of High Growth - The high growth in performance is driven by three main factors: 1) Continued commercialization and sales growth of core products, particularly Tai Tasi P and Vidi Sima Tan in the mainland China market [2] 2) Significant profit enhancement from BD income recognition, including licensing agreements with Vor Biopharma and Santen Pharmaceutical [2] 3) Ongoing optimization of operational efficiency, leading to improved gross margins and a noticeable decrease in sales expense ratios [2] Group 3: Future Outlook - The company is optimistic about the overseas registration progress of key products, including the MGIII phase enrollment for Tai Tasi P and the initiation of the SSIII phase [3] - Anticipated sales growth in mainland China following the inclusion of Tai Tasi P for MG indications in medical insurance, along with approvals for larger indications such as SS and IgAN [3] - Progress in early-stage products like RC148 and RC118 in additional indications, with data readouts expected to catalyze stock price [3]